Bendamustine-based Combination Therapy for PCNSL

Inclusion Criteria:

1. PCNSL of diffuse large B-cell lymphoma (DLBCL) with a CNS lesion by tissue biopsy
2. Age ≥ 19 years old
3. Relapsed or refractory PCNSL after frontline combined chemotherapy or radiation
4. ECOG performance status 0-2
5. Absolute neutrophil count ≥ 1000/uL
6. Platelets ≥ 100,000/uL
7. Total bilirubin ≤ 1.5 x ULN (upper limit of normal)
8. Aspartate aminotransferase (AST) ≤ 3 x ULN
9. Creatinine ≤ 2.0 x ULN

Exclusion Criteria:

1. PCNSL of other than DLBCL or T-cell lymphoma with a CNS lesion by tissue biopsy
2. Any of the following: pregnant women, nursing women, men or women of childbearing potential who are unwilling to employ adequate contraception
3. Uncontrolled infection
4. Therapy with myelosuppressive chemotherapy or biologic therapy \< 21 days prior to registration
5. Persistent toxicities ≥ grade 3 from prior chemotherapy or biologic therapy regardless of interval since last treatment
6. History of thromboembolic episodes ≤ 3 months prior to registration
7. Active hepatitis B or C with uncontrolled disease
8. Active other malignancy requiring treatment that would interfere with the assessments of response of the lymphoma to protocol treatment
9. Any severe and/or uncontrolled medical conditions or other conditions that could adversely impact their ability to participate in the study
10. Major surgery ≤ 4 weeks prior to registration or have not recovered from side effects of such therapy